Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marc Gitzinger | M | - |
BioVersys AG
 BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | 16 years |
| William John Jenkins | M | 77 |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
| Seng Chin Mah | M | - |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
| Daniel O.A. Rüedi | M | - |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
| David Hunstad | M | - |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 5 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marina von Schönau
- Personal Network
